Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB.
The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, SopartecS. A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio PharmaB. V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH.
It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | 1.39 Increased by +211.20% | 0.03 Increased by +4.53 K% |
| Jul 25, 24 | 0.45 Increased by +126.63% | -0.98 Increased by +145.92% |
| May 9, 24 | -1.04 Decreased by -46.48% | -0.86 Decreased by -20.93% |
| Feb 29, 24 | -1.68 Decreased by -140.00% | -1.70 Increased by +1.18% |
| Oct 31, 23 | -1.25 Increased by +70.66% | -1.54 Increased by +18.83% |
| Jul 27, 23 | -1.69 Increased by +55.53% | -1.73 Increased by +2.31% |
| May 7, 23 | -0.71 Increased by +83.72% | -2.26 Increased by +68.58% |
| Mar 2, 23 | -0.70 Increased by +86.17% | -2.93 Increased by +76.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 573.24 M Increased by +73.82% | 91.41 M Increased by +225.84% | Increased by +15.95% Increased by +172.40% |
| Jun 30, 24 | 877.26 M Increased by +224.25% | -32.48 M Increased by +65.58% | Decreased by -3.70% Increased by +89.39% |
| Mar 31, 24 | 401.00 M Increased by +82.99% | -61.60 M Decreased by -113.35% | Decreased by -15.36% Decreased by -16.59% |
| Dec 31, 23 | 401.00 M Increased by +130.25% | -61.60 M Decreased by -59.52% | Decreased by -15.36% Increased by +30.72% |
| Sep 30, 23 | 329.79 M Increased by +139.01% | -72.64 M Increased by +69.09% | Decreased by -22.03% Increased by +87.07% |
| Jun 30, 23 | 270.55 M Increased by +259.80% | -94.37 M Increased by +54.79% | Decreased by -34.88% Increased by +87.44% |
| Mar 31, 23 | 219.14 M Increased by +836.02% | -28.87 M Increased by +87.29% | Decreased by -13.17% Increased by +98.64% |
| Dec 31, 22 | 174.16 M Increased by +569.28% | -38.61 M Increased by +83.76% | Decreased by -22.17% Increased by +97.57% |